Citigroup Begins Coverage on Acumen Pharmaceuticals (NASDAQ:ABOS)
Citigroup initiated coverage on shares of Acumen Pharmaceuticals (NASDAQ:ABOS – Free Report) in a research report sent to investors on Tuesday, Marketbeat reports. The brokerage issued a buy rating and a $4.00 price objective on the stock. Several other research analysts also recently issued reports on the stock. HC Wainwright reduced their price target on […]
Citigroup initiated coverage on shares of Acumen Pharmaceuticals (NASDAQ:ABOS – Free Report) in a research report sent to investors on Tuesday, Marketbeat reports. The brokerage issued a buy rating and a $4.00 price objective on the stock. Several other research analysts also recently issued reports on the stock. HC Wainwright reduced their price target on […]
